C2 PHARMA, a leader in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), recently launched Naphazoline Hydrochloride, expanding its ophthalmic API portfolio, while it also received approval for a Certificate of Suitability (CEP) for Tropicamide.   “Our global leadership in ophthalmic APIs is underpinned by our willingness to set the bar higher at all levels,” states Andrew Badrot, CEO of C2 PHARMA. “We are committed to providing our customers APIs...